ABN 16 165 160 841

ASX RELEASE **9 May 2023**

ACCENT Trial Recruitment Progress

HIGHLIGHTS:

- Enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial is now complete.

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.

Amplia's CEO and Managing Director Dr Chris Burns commented: "We are very pleased to have completed recruitment of Cohort 3, despite the disruption of holidays in April. This achievement reflects the enthusiasm and commitment of the clinical trial sites in Melbourne, Sydney and Brisbane which has allowed recruitment for this cohort to be completed within one month of opening enrolment. As always, we thank the patients for consenting to be part of the trial."

The first stage of the ACCENT trial is designed to test ascending doses of AMP945 given in combination with standard-of-care chemotherapy of gemcitabine and nab-paclitaxel, in patients with advanced pancreatic cancer. After 1 month of treatment, the trial's Safety Committee will review the clinical data collected and, subject to the data, determine next steps in the trial.

About the ACCENT Trial

The protocol for the ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The trial is to be conducted in two stages. The first, Phase 1b stage of the trial, is a single-arm open label study to select an optimal dose of AMP945 by assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AMP945 when dosed in combination with gemcitabine and nab-paclitaxel (Abraxane®) in first-line patients with advanced pancreatic cancer.

The second, Phase 2a, stage of the trial is also a single-arm open label study and is designed to perform an assessment of the optimal dose of AMP945, in combination with gemcitabine and nab-paclitaxel, with the primary endpoint being Objective Response Rate (ORR). Further endpoints will assess efficacy by other means as well as safety and tolerability.

More information about the ACCENT trial, including a list of participating sites, can be found via our website and at ClinicalTrials.gov under the identifier NCT05355298. The Company will provide further updates on the trial as recruitment proceeds.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn.